AbbVie Inc (ABBV)vsSINTX Technologies Inc (SINT)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
SINT
SINTX Technologies Inc
$1.80
-3.23%
HEALTHCARE · Cap: $10.86M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4840953% more annual revenue ($64.39B vs $1.33M). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
SINT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for SINT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 199.3% year-over-year
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : SINT
The strongest argument for SINT centers on Revenue Growth, Price/Book. Revenue growth of 199.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : SINT
The primary concerns for SINT are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while SINT is a hypergrowth play — different risk/reward profiles.
SINT carries more volatility with a beta of 0.64 — expect wider price swings.
SINT is growing revenue faster at 199.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 28/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
SINTX Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sintx Technologies, Inc., an advanced materials company, researches, develops, manufactures, and markets silicon nitride ceramics in the United States, Europe, and South America. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?